NAD+ Research Guide

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell. It cycles between oxidized (NAD+) and reduced (NADH) states and serves as an electron carrier in central metabolism. Beyond redox chemistry, NAD+ is the obligate substrate of sirtuins, PARPs, and CD38 — three enzyme families that consume the molecule during signaling.

Why NAD+ has become a research target

• Tissue NAD+ pools decline with age in many mammalian models, in parallel with mitochondrial dysfunction.
• Pharmacological restoration of NAD+ in pre-clinical models has been associated with improvements in metabolic, neuromuscular, and inflammatory endpoints.
• Sirtuins (SIRT1–7) and PARPs depend on NAD+ for deacetylation and DNA-damage-response activity respectively.

Precursors

The salvage pathway recycles nicotinamide back to NAD+ via NAMPT. Common research precursors include nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Direct NAD+ is studied in IV and lyophilized formats in laboratory settings.

Handling

Lyophilized NAD+ is stored cold, dry, and protected from light. After reconstitution, solutions are typically used promptly; NAD+ is sensitive to elevated pH and heat.

Quality control

NAD+ research vials ship with a per-batch COA. See the COA education article to interpret it.

References (representative)

• Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015.
• Rajman L, et al. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018.